MEIP - MEIファ―マ (MEI Pharma Inc.) MEIファ―マ

 MEIPのチャート


 MEIPの企業情報

symbol MEIP
会社名 MEI Pharma Inc (MEIファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 MEIファーマ(MEI Pharma Inc.)(旧名:Marshall Edwards Inc)はがんの治療向けの薬物と治療の臨床開発に焦点を当てる癌治療に従事する会社である。同社の臨床薬候補のポートフォリオには、Pracinostat、ME-344及びME-401が含まれる。Pracinostatは、経口で利用可能なヒストンデアセチラーゼ(HDAC)阻害剤であり、急性骨髄性白血病(AML)と骨髄異形成症候群(MDS)などの血液疾患の治療に適応する。ME-344は、イソフラボン系ミトコンドリア阻害剤であり、急速に増殖する細胞中の末端呼吸鎖複合体のミトコンドリア成分を標的とする。ME-401は、血液癌細胞の増殖と生存に重要な役割を果たす分子標的であるホスファチジルイノシトイド3-キナーゼ(PI3K)デルタの経口阻害剤である。Pracinostatは、進行性血液悪性腫瘍と固形腫瘍適応症における複数の第I相と第II相臨床試験で試験される。  MEIファ―マは米国の腫瘍専門の医薬品メ―カ―。がん治療のための新薬の臨床開発に従事。主力製品候補の「Pracinostat」は、骨髄異形成症候群や急性骨髄性白血病などの進行性の血液疾患のために開発されている、経口投与可能なヒストンデアセチラ―ゼ阻害剤である。本社はサンディエゴ。   MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options.
本社所在地 3611 Valley Centre Drive Suite 500 San Diego CA 92130 USA
代表者氏名 Christine Anna White クリスティーナ・アンナ・ホワイト
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-792-6300
設立年月日 36861
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.meipharma.com
nasdaq_url https://www.nasdaq.com/symbol/meip
adr_tso
EBITDA EBITDA(百万ドル) -28.53300
終値(lastsale) 3.75
時価総額(marketcap) 266574015
時価総額 時価総額(百万ドル) 266.68290
売上高 売上高(百万ドル) 1.62200
企業価値(EV) 企業価値(EV)(百万ドル) 163.93990
当期純利益 当期純利益(百万ドル) -40.06800
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 MEI Pharma Inc revenues decreased 93% to $1.6M. Net loss totaled $40.1M vs. income of $2.7M. Revenues reflect License revenue decrease from $20.9M to $0K Research and development revenue decrease of 32% to $1.6M. Net loss reflects Research and development - Balancing val increase from $6.4M to $15.9M (expense) General and administrative - Balancing v increase of 8% to $7.7M (expense).

 MEIPのテクニカル分析


 MEIPのニュース

   MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)  2021/07/01 20:01:00 Benzinga
SAN DIEGO , July 1, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP ), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 169,000 shares of the company''s common stock to three new employees. The stock options were granted as a material inducement to each new employee accepting employment with MEI in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a $2.85 exercise price per share, which is equal to the closing price of the Company''s common stock on the grant date. The options were granted pursuant to the MEI Pharma, Inc. 2021 Inducement Grant Equity Compensation Plan, and have terms and conditions consistent with the MEI Pharma, Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. The options were approved by the Company''s Compensation Committee of the Board of Directors in reliance on the employment inducement exception under Rule 5635(c)(4), which requires that grants relying on this exception be disclosed promptly in a press release.
   MEI Pharma Consensus Indicates Potential 223.6% Upside  2021/06/27 14:49:13 DirectorsTalk
MEI Pharma found using ticker (MEIP) have now 10 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 13 and 5.5 calculating the average target price we see 9.45. With the stocks previous close at 2.92 this would imply there is a potential upside of 223.6%. There is a 50 day moving average of 2.86 and the 200 day MA is 3.08. The market cap for the company is $344m. Visit the company website at: /> [stock_market_widget type="chart" symbol="MEIP" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] MEI Pharma, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.
   MEI Pharma (MEIP) Receives a Buy from H.C. Wainwright  2021/06/11 10:16:22 Smarter Analyst
In a report released today, Andrew Fein from H.C. The post MEI Pharma (MEIP) Receives a Buy from H.C. Wainwright appeared first on Smarter Analyst .
   MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program  2021/06/09 00:00:00 BioSpace
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma to be held June 18 22, 2021.
   MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib  2021/06/07 00:00:00 BioSpace
MEI Pharma, Inc. (NASDAQ: MEIP), and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,
   MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update  2021/01/04 12:00:00 PR Newswire
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase ("PI3K")…
   MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP  2020/12/19 03:50:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into MEI Pharma, Inc. (NasdaqGS: MEIP). From August 2017, the Company repeatedly touted the potency and effectiveness of its drug candidate, Pracinostat, in its Phase 2 trial. However, on July 2, 2020, the Company disclosed that it was discontinuing the Phase 3 trial of Pracinostat, due
   MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2020. "As we move through fiscal year 2021, we are well-positioned and…
   Myelodysplastic Syndromes (MDS) Market Overview, Outlook, Recent Trend By 2026 | Otsuka Holdings, Lupin, Johnson & Johnson, MEI Pharma, Mylan N.V.  2020/11/03 06:10:10 OpenPR
This Myelodysplastic Syndromes (MDS) Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness,
   Zacks: Brokerages Expect MEI Pharma Inc (NASDAQ:MEIP) Will Post Earnings of -$0.07 Per Share  2020/10/24 14:12:43 Transcript Daily
Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for MEI Pharma’s earnings. MEI Pharma reported earnings of ($0.17) per share in the same quarter last year, which indicates a positive year over year growth rate of […]
   MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Highlights  2020/11/10 21:05:00 PR Newswire
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2020. "As we move through fiscal year 2021, we are well-positioned and…
   Myelodysplastic Syndromes (MDS) Market Overview, Outlook, Recent Trend By 2026 | Otsuka Holdings, Lupin, Johnson & Johnson, MEI Pharma, Mylan N.V.  2020/11/03 06:10:10 OpenPR
This Myelodysplastic Syndromes (MDS) Market research report is a great store to acquire current as well as upcoming technical and financial details of the industry for the precise forecast period. This market report also provides information about the brand awareness,
   Zacks: Brokerages Expect MEI Pharma Inc (NASDAQ:MEIP) Will Post Earnings of -$0.07 Per Share  2020/10/24 14:12:43 Transcript Daily
Analysts expect MEI Pharma Inc (NASDAQ:MEIP) to report earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for MEI Pharma’s earnings. MEI Pharma reported earnings of ($0.17) per share in the same quarter last year, which indicates a positive year over year growth rate of […]
   Lifesci Capital Reaffirms “Outperform” Rating for MEI Pharma (NASDAQ:MEIP)  2020/10/24 06:46:44 Transcript Daily
Lifesci Capital reissued their outperform rating on shares of MEI Pharma (NASDAQ:MEIP) in a report published on Wednesday, Zacks.com reports. Several other brokerages have also recently weighed in on MEIP. SunTrust Banks reduced their price target on MEI Pharma from $16.00 to $12.00 in a research report on Monday, July 6th. Ci Capital restated a […]
   Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders  2020/10/23 22:22:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. One of MEI Pharma's drug candidates include Pracinostat, an oral histone de

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 MEIファ―マ MEIP MEI Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)